Abstract
Complications associated with the infusion of blood and blood products are not uncommon. They can present as acute reactions occurring during, or within a few hours of the transfusion, or as delayed events, presenting days or possibly years later (Table 1). Patient morbidity is variable depending on the type of reaction and with some reactions mortality can occur [1,2].
This manuscript was supported in part by grants from the Miles-CRC Research Fund and the Medical Research Council of Canada.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Heddle NM. Noninfectious adverse reactions to blood transfusion. In: Current Therapy In Haematology-Oncology. Brain MC, Carbone PP, eds, Mosby-YearBook Inc., St. Louis, MI, 1995:p225–30.
AABB Annual Meeting Serminar. In: Transfusion-Transmitted Viral Diseases, Moore SB (ed) American Association of Blood Banks, Arlington, VA, 1987.
Davenport RD, Kunkel SL. Cytokine roles in hemolytic and nonhemolytic transfusion reactions. Transf Med Rev 1994;VIII: 157–68.
Muylle L, Joos M, Wouters E, de Bock R, Peetermans ME. Increased tumour necrosis factor α (TNFα), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: relationship between TNFα and IL-6 levels and febrile transfusion reactions. Transfusion 1993;33:195–99.
Silliman C, Thurman G, Ambruso D. Agents that prime the neutrophil (PMN) oxidase develop during routine storage of platelet concentrates. Blood 1992;80:365a.
Stack G, Snyder EL. Cytokine generation in stored platelet concentrates. Transfusion 1994;34:20–25.
Aye MT, Palmer DS, Giulivi A, Hashemi S. Effect of filtration of platelet concentrates on the accumulation of cytokines and platelet release factors during storage. Transfusion 1995;35:117–24.
Schleuning M, Bock M, Mempel W. Complement activation during storage of single-donor platelet concentrates. Vox Sang 1994;67:144–48.
Heddle NM, Klama L, Singer J, et al. The role of the plasma supernatant from platelet concentrates in transfusion reactions. N Engl J Med 1994;331:625–28.
Muylle L, Peetermans ME. Effect of prestorage leukocyte removal on the cytokine levels in stored platelet concentrates. Vox Sang 1994;66:14–17.
Kluter H, Müller-Steinhardt M, Danzer S, Wilhelm D, Kirchner H. Cytokines in platelet concentrates prepared from pooled buffy coats. Vox Sang 1995;69:38–43.
Miletic VD, Popovic O. Complement activation in stored platelet concentrates. Transfusion 1993;33:150–54.
Silliman CC, Clay KL, Thurman GW, Johnson CA, Ambruso DR. Partial characterization of lipids that develop during the routine storage of blood and prime the neutrophil NADPH oxidase. J Lab Clin Med 1994;124:684–94.
Snyder EL. Removal of complement chemokines and other soluble biological response modifiers, by Pall bedside leukoreduction and plasma filter. Bloodlink, Pall Biomedical Products Company, Vol. 4, 1995.
Snyder EL, Stack G. Febrile and nonimmune transfusion reactions. In: Rossi EC, Simon TL, Moss GS, eds. Principles of transfusion medicine. Baltimore: Williams & Wilkins, 1996:641–60.
Decary F, Ferner P, Giavedoni L, et al. An investigation of nonhaemolytic transfusion reactions. Vox Sang 1984;46:277–85.
Heddle NM, Klama L, Ball S, Tan MK, Christmas T. The effect of blood product preparation on cytokine levels. Transfusion 1996;36(Suppl):15.
Darbonne WC, Rice GC, Mohler MA, et al. Red blood cells are a sink for interleukin 8, a leukocyte chemotaxin. J Clin Invest 1991;88: 1362–69.
Heddle N, Tan M, Klama L, Shroeder J. Factors affecting cytokine production in platelet concentrates. Transfusion 1994;34:67S.
Frewin DB, Jonsson JR, Head RJ, Russell WJ, Beal RW. Histamine levels in stored human blood. Transfusion 1984;24:502–04.
Sackett DL, Haynes RB, Tugwell P. Clinical Epidemiology. A Basic Science for Clinical Medicine. Boston, MA, Little, Brown, 1985.
Guyatt GH, Sackett DL, Cook DJ. Evidence-based medicine: User’s guide to the medical literature. II. How to use an article about therapy or prevention. Part A. Are the results of the study valid? JAMA 1994;271:59–63.
Guyatt GH, Sackett DL, Cook DJ. Evidence-based medicine: User’s guide to the medical literature. II. How to use an article about therapy or prevention. Part B. What are the results and will they help me in caring for my patients? JAMA 1993;270: 2598–601
Walker RH, ed. Technical manual. 10th ed. Arlington: American Association of Blood Banks, 1990:420.
Payne R. The association of febrile transfusion reactions with leuko-agglutinins. Vox Sang 1957;2:233–41.
Payne R, Rolfs MR. Further observations on leukoagglutinin transfusion reactions. With special reference to leukoagglutinin transfusion reactions in women. Am J Med 1960;30:449–58.
Perkins HA, Payne R, Ferguson J, Wood M. Nonhaemolytic febrile transfusion reactions. Quantitative effects of blood components with emphasis on isoantigenic incompatibility of leukocytes. Vox Sang 1966;11:578–600.
Menitove JE, McElligott MC, Aster RH. Febrile transfusion reaction: what blood component should be given next? Vox Sang 1982;41:318–21.
Chambers LA, Kruskall MS, Pacini DG, Donovan LM. Febrile reactions after platelet transfusion: the effect of single versus multiple donors. Transfusion 1990;30:219–21.
Mangano MM, Chambers LA, Kruskall MS. Limited efficacy of leukopoor platelets for prevention of febrile transfusion reactions. Am J Clin Pathol 1991;95:733–38.
Heddle NM, Klama LN, Griffith L, Roberts R, Shukla G, Kelton JG. A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions. Transfusion 1993;33:794–97.
Muylle L, Wouters E, de Bock R, Peetermans ME. Reactions to platelet transfusion: the effect of the storage time of the concentrate. Transfus Med 1992;2:289–93.
Muylle L. Ex vivo Cytokine Production in Blood Components: Relevant or Irrelevant. Kluwer Academic Publishers: London, Vol 32, 1994.
Heddle NM, Kelton JG. Febrile non-haemolytic transfusion reactions. AABB Press 1996.
Shimizu T, Uchigiri C, Mizuno S, Kamiya T, Kokubo Y. Adsorption of anaphylatoxins and platelet-specific proteins by filtration of platelet concentrates with a polyester leukocyte reduction filter. Vox Sang 1994;66:161–65.
Snyder E, Napychank P, Baril L. Removal of complement component C3a and inter-leukin-8 from platelet concentrate by a bedside leukodepletion filter. Transfusion 1994; 34(Suppl):31S.
Whitebread J, Besso N, Onunka V, Brandwein H. Reduction of C3A fragment levels following leukodepletion using a Pall PXL8 filter. Transfusion 1994;84:672a.
Hed J, Johansson M, Lindroth M. Complement activation according to the alternate pathway by glass and plastic surfaces and its role in neutrophil adhesion. Immunology Letters 1984;8:295–99.
Sevast’ianov VI, Tseytlina EA. The activation of the complement system by polymer materials and their blood compatibility. J Biomed Res 1984;18:969–78.
Oksanen K, Ebeling F, Kekomäki R, et al. Adverse reactions to platelet transfusions are reduced by use of platelet concentrates derived from buffy coat. Vox Sang 1994;67: 356–61.
Anderson KC, Gorgone BC, Wahlers E, Cook J, Barrett B, Andersen J. Preparation and clinical utility of leukocyte poor apheresis platelets. Transfus Sci 1991;12:163–70.
Dzieczkowski JS, Barrett BB, Nester D, et al. Characterization of reactions after exclusive transfusion of white cell-reduced cellular blood components. Transfusion 1995;35: 20–5.
Federowicz I, Barrett BB, Andersen JW, Urashima M, Popovsky MA, Anderson KC. Characterization of reactions after transfusion of cellular blood components that are white cell reduced before storage. Transfusion 1996;36:21–28.
Muir JC, Jacobson S, Herschel L, AuBuchon JP. Does pre-storage leukocyte reduction of blood components reduce the risk of febrile reactions in sensitized patients? Blood 1994;84(Suppl):1842.
Muir JC, Herschel L, Pickard C, auBuchon JP. Pre-storage leukocyte reduction decreases the risk of febrile reactions in sensitized platelet recipients. Transfusion 1995; 35(Suppl):45S.
Sacher RA. High circulating interleukin 6 levels associated with acute transfusion reaction: cause or effect? Transfusion 1993;33:962(letter).
Popovsky MA, Chaplin HC Jr, Moore SB. Transfusion-related acute lung injury: a neglected, serious complication of haemotherapy. Transfusion 1992;32:589–92.
Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985;25:573–77.
Rot A. Some aspects of NAP-1 pathophysiology: lung damage caused by a blood-borne cytokine. Adv Exp Med Biol 1991;305:127–35.
Kunkel SL, Standiford T, Kasahara K, Strieter RM. Interleukin-8 (IL-8): the major neutrophil chemotactic factor in the lung. Exp Lung Res 1991;17:17–23.
Silliman C, Pitman J, Thurman G, Ambruso D. Neutrophil (PMN) priming agents develop in patients with transfusion related acute lung injury. Blood (Suppl.) 1992; 261a.
Jeter EK, Spivey MA. Noninfectious complications of blood transfusion. Haematology/Oncology Clinics of North American 1995:9:187–204.
Frewin DB, Jonsson JR, Davis KG, et al. Effect of microfiltration on the histamine levels in stored human blood. Vox Sang 1987; 52:191–94.
Frewin DB, Jonsson JR, Frewin CR, et al. Influence of blood storage time and plasma histamine levels on the pattern of transfusion reactions. Vox Sang 1989;56:243–56.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Kluwer Academic Publishers
About this chapter
Cite this chapter
Heddle, N.M. (1997). Clinical Relevance of Cytokine Levels in Blood Products: Evidence to Correlate with Morbidity. In: Sibinga, C.T.S., Das, P.C., Löwenberg, B. (eds) Cytokines and Growth Factors in Blood Transfusion. Developments in Hematology and Immunology, vol 32. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1137-9_11
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1137-9_11
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8435-2
Online ISBN: 978-1-4613-1137-9
eBook Packages: Springer Book Archive